Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

Aims To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus. Methods This parallel‐group, open‐label, dose‐escalation study examined the PK and GD of basal insulin LY2605541 after single and multiple‐dose administration. Fixed doses of LY2605541 (0.33–1.00 U/kg) were given once‐daily (QD) for 14 days to insulin‐treated patients with type 2 diabetes. A 24‐h euglycaemic glucose clamp was conducted on days 1 and 14. Results PK steady state was achieved within 7–10 days and the peak‐to‐trough fluctuation was